Recently, Tianjin Municipal Science and Technology Bureau urgently launched "COVID-19 Infection Emergency Prevention and Control" science and technology major special commencement scheme. Enterprises in the field of life and health in Wuqing Development Area gave full play of technical advantages, actively applied and declared, carried out research on tackling key problems around key scientific and technological issues of the COVID-19 diagnosis and treatment, and contributed to the victory of defeating COVID-19. The project undertaken by GensKey Medical Science and Technology Co., Ltd. has obtained approval of the first batch of major science and technology projects; and the projects undertaken by Tianjin Chase Sun Pharmaceutical Co., Ltd. and Tianjin BMC Medicial Co., Ltd. have obtained the approval of the second batch of major science and technology projects.
The approved projects are:
01 "Development and Registration for Certificate of a COVID-19 Virus Nucleic Acid Detection Kit Based on Polymerase Chain Reaction and High-throughput Sequencing"
The undertaken unit of the project by Tianjin Gens Key Medical Science and Technology Co., Ltd. After the outbreak of the epidemic, Gens Key Medical added the COVID-19 virus genomic sequence to the pathogen database at the 1st time, developed the sequencing detection kit for the COVID-19 virus, data analysis software and the fluorescent RT-PCR nucleic acid detection kit. It took the ORF1ab gene and the N gene in the ORF1ab fragment of the COVID-19 as target area, and introduced the internal control markers to realize the stable detection of the virus nucleic acid. At the same time, it actively establishes innovative technology evaluation system for molecular diagnosis of COVID-19 (2019-nCoV) and a quality control system in line with the national standards for medical device evaluation in order to quickly complete the development and registration of related products.
02 "Prospective Cohort Study on the Efficacy of Xuebijing Intravenous in the Treatment of COVID-19-Infected Pneumonia"
The undertaken unit of the project is Tianjin Chase Sun Pharmaceutical Co., Ltd., the First Affiliated College of Guangzhou Medical University and Guangzhou Institute of Respiratory Health. The project is in the charge of Zhong Nanshan, academician of Chinese Academy of Engineering, famous expert of respiratory, current director of National Clinical Research Center for Respiratory Diseases and head of high-level expert group of National Health Commission, in person.
Based on that Xuebijing has already have the evidence-based accumulation in the treatment of severe pneumonia and sepsis, it may have a good effect on COVID-19. Led by Academician Zhong Nanshan, while treating the patients of COVID-19, this project was set up for carrying out the prospective study. It took the observation of efficacy of Xuebijing in the treatment of COVID-19, with the pneumonia severity index (PSI) as the main evaluation index, and the 28-day survival rate of the follow-up patients as the end point of the study to evaluate the efficacy of Xuebijing intravenous on COVID-19. The preliminary analysis indicated that the effective rate of Xuebijing in treating severe COVID-19 was 95.8%, and the risk rating of pneumonia severity index and SOFA score were significantly decreased after treatment (P <0.05), and preliminary consideration is that the Xuebijing is effective.
03 "Research and Development of High Flow Humidity Oxygen Therapy System for COVID-19 Epidemic"
The undertaken unit of the project was Tianjin BMC Medical Co., Ltd., Tiangong University, Tianjin Chest Hospital, Tianjin Jueming Science and Technology Co., Ltd., and Hubei Enshi State Center Hospital.
The project carried out the research on the wireless high-flow humidification oxygen therapy system in the scene of oxygen therapy for the multi-patients in the epidemic areas, and has completed the research and evaluation of clinical applicability. BMC Medical cooperated with the first-line hospitals to improve the hardware of high-flow humidification oxygen therapy system, build wireless network platform and central monitoring system and realize wireless remote monitoring of key parameters of multi-equipment and vital signs of patients, which can not only improve the efficiency of treatment, but also effectively prevent the cross-contaminations caused by droplets and the like.
The life and health industry is one of the leading industries in the development area. The park has formed a life and health industry cluster, which mainly consists of gene sequencing, traditional Chinese medicine granules, medical devices and diagnostic reagents. Next, the development area will focus on the "epidemic prevention" and "development", takes the "five major innovation platforms" as the starting point, and strive to create a fully functional and dynamic innovation system to provide strong support to the innovation and development of the enterprises.
News 
Contact Us
Home